Theravance Biopharma (TBPH) Leases (2019 - 2025)
Theravance Biopharma (TBPH) has disclosed Leases for 7 consecutive years, with $24.4 million as the latest value for Q4 2025.
- Quarterly Leases fell 14.05% to $24.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.4 million through Dec 2025, down 14.05% year-over-year, with the annual reading at $24.4 million for FY2025, 14.05% down from the prior year.
- Leases for Q4 2025 was $24.4 million at Theravance Biopharma, down from $25.4 million in the prior quarter.
- The five-year high for Leases was $42.5 million in Q1 2021, with the low at $24.4 million in Q4 2025.
- Average Leases over 5 years is $35.3 million, with a median of $38.0 million recorded in 2023.
- The sharpest move saw Leases grew 1.1% in 2022, then dropped 22.44% in 2025.
- Over 5 years, Leases stood at $39.7 million in 2021, then grew by 1.1% to $40.1 million in 2022, then fell by 9.57% to $36.3 million in 2023, then dropped by 21.86% to $28.4 million in 2024, then decreased by 14.05% to $24.4 million in 2025.
- According to Business Quant data, Leases over the past three periods came in at $24.4 million, $25.4 million, and $26.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.